SOPHiA GENETICS reported third-quarter 2026 revenue of $24.3 million, up 25% year-over-year. Net loss was $20.3 million, up 1%, while adjusted EBITDA loss improved 31% to $6.1 million. The company now expects full-year revenue at the upper end of its $94 million to $96 million guidance. It expects an adjusted EBITDA loss of $29 million to $32 million, compared with $41.5 million in 2025. It signed 30 new genomics customers and closed three material BioPharma deals, including two companion diagnostic programs with AstraZeneca. Revenue in the US rose 41%, and analysis volume hit a record 118,000. Chief executive officer Ross Muken said the company is moving closer to profitability. It aims to reach positive adjusted EBITDA in the second half of 2027.

SOPHiA GENETICS reports third Quarter 2026 results. Nov 03, 2026, 06:45 ET BOSTON and ROLLE, Switzerland, Nov. 3, 2026 /PRNewswire/ - SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights * Revenue was $24.3 million, up 25% year-over-year on a reported basis * Gross margin was 65.7% on a reported basis and 72.8% on an adjusted basis, compared to 66.3% reported and 73.1% adjusted in the prior year period * Net loss was $20.3 million, up 1% year-over-year; Adjusted EBITDA loss was $6.1 million, improving 31% year-over-year * The company now expects full-year 2026 revenue to be at the upper end of its previously issued guidance range of $94 million to $96 million, reflecting strong business performance partially offset by the impact of foreign exchange rate movements at the end of the third quarter, which, if sustained, would be a headwind to fourth-quarter revenue. "Record analysis volume, strong performance in the U.S. market, and accelerating BioPharma momentum resulted in another excellent quarter as revenue grew 25% year-over-year," said Ross Muken, Chief Executive Officer of SOPHiA GENETICS. "We also meaningfully improved adjusted EBITDA by 31%, bringing us closer to profitability and further demonstrating the highly scalable nature of our AI-native platform and business model." "Looking ahead, new geographies, exciting new products, and expanded relationships with BioPharma offer meaningful catalysts for future growth. We signed 30 new genomics customers in Q3 and closed three material BioPharma deals, including two companion diagnostic programs and a new, multimodal AI project announced today. These partnerships position us well for 2027 and further extend the reach of our clinical intelligence to more patients worldwide." Business Highlights Expanding with existing customers * Performed a record 118,000 analyses on SOPHiA DDM(TM), representing 19% year-over-year volume growth * Delivered strong growth in North America (NORAM) and Asia Pacific (APAC) with 45% and 33% year-over-year revenue growth, respectively * Expanded our footprint with existing customers as Net Dollar Retention increased to 118% in Q3 2026, up from 108% in Q3 2025 * Reached 551 core genomics customers as of September 30, 2026, up from 488 customers in the prior year period Landing new customers to fuel future growth * Signed 30 new core genomic customers in Q3 2026, which are expected to begin generating revenue over the next twelve months * Continued to sign premier healthcare institutions across the globe, including University of Newcastle, a globally renowned research university in Australia, for Rare Disorders; King Chulalongkorn Memorial Hospital, one of the most prestigious academic medical centers in Thailand, for Solid Tumors and HemOnc; and HBIOMOL, an established diagnostics network in Brazil, for Rare Disorders Accelerating growth in the U.S. market * Achieved 41% year-over-year revenue growth in the U.S. in Q3 2026 * Signed two new customers in the U.S., including PathGroup, one of the largest physician-led pathology and clinical laboratory service providers in the U.S., for Solid Tumors and HemOnc, and the University of Arkansas for Medical Sciences (UAMS), Arkansas's only health sciences university and largest public employer, for HemOnc; these accounts are expected to ramp up in 2027 * Expanded our long-standing partnership with the Molecular Diagnostics Laboratory at the University of North Carolina (UNC) Medical Center to adopt HemOnc, Hereditary Cancer, and Rare Disorders applications, in addition to applications they currently run today * Signed a notable expansion deal with a leading U.S. military medical center, valued at over $2 million per year, for Rare Disorders applications Scaling growth with new applications * Performed 4,200 Liquid Biopsy analyses in Q3 2026, up 100%+ year-over-year, as more customers continue to implement the application and ramp usage * Signed major new customers to MSK-ACCESS(R) powered with SOPHiA DDM(TM) in Q3, including University Hospital Augsburg, one of the largest university hospitals in Germany; Agilus Diagnostics, one of the largest diagnostic laboratory networks in India; and Hanusch Krankenhaus, a leading hospital in Austria * Signed major new customers to the Solid Tumor application MSK-IMPACT(R) powered with SOPHiA DDM(TM), including AOU Pisana, a leading university hospital in Italy; Géntodos, an emerging genomics company in Mexico; and Ruhr University Bochum, a large academic pathology institute in Germany Building BioPharma partnerships * Signed a new multimodal AI collaboration with a top BioPharma company to develop a multimodal AI predictor to help identify which bladder cancer patients are most likely to benefit from a targeted therapy * Signed a multi-year agreement with AstraZeneca in Q3 to launch two companion diagnostic (CDx) programs: (1) a decentralized Solid Tumor CDx, and (2) a Hematological Oncology test for patients with blood cancer * Announced additional details on the Solid Tumor CDx, including the incorporation of Myriad Genetics' novel prostate cancer-specific genomic instability score (PrGIS) technology into the Extended Homologous Recombinant Solution (HRS), powered by SOPHiA DDM(TM) * Delivered strong growth from BioPharma partners in Q3 2026 as recently signed projects continue to generate revenue Driving operational excellence * Remained laser-focused on operational excellence and improved adjusted EBITDA loss by 31% year-over-year to $6.1 million * Reaffirmed commitment to profitable growth and crossing over to positive adjusted EBITDA in the second half of 2027 2026 Financial Outlook Based on information as of today, SOPHiA GENETICS expects: * Full year revenue to be at the upper end of its previously issued guidance range of $94 million to $96 million, reflecting strong business performance partially offset by the impact of foreign exchange rate movements at the end of the third quarter, which, if sustained, would be a headwind to fourth-quarter revenue. * Adjusted EBITDA loss between $29 million and $32 million, compared to $41.5 million in FY 2025 Earnings Call and Webcast Information SOPHiA GENETICS will host a conference call and live webcast to discuss the third quarter 2026 results on Tuesday, November 3, 2026, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time. The call will be webcast live on the SOPHiA GENETICS Investor Relations website, ir.sophiagenetics.com. Additionally, an audio replay of the conference call will be available on the SOPHiA GENETICS website after its completion. Non-IFRS Financial Measures Other than with respect to revenue, the Company only provides guidance on a non-IFRS basis. The Company does not provide a reconciliation of forward-looking adjusted gross margin (non-IFRS measure) to gross margin (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying amortization of capitalized research & development expenses that are necessary for such reconciliation. In addition, the Company does not provide a reconciliation of forward-looking adjusted EBITDA (non-IFRS measure) to loss for the period (the most comparable IFRS financial measure), due to the inherent difficulty in forecasting and quantifying depreciation expense, amortization of capitalized research & development expenses and intangible assets, interest income, interest expense, fair value adjustments on warrants, income taxes, foreign exchange gains or losses, share-based compensation expenses, social charges on share-based compensation, the non-cash portion of pensions paid in excess of actual contributions, certain transaction costs, litigation expenses and restructuring costs that are necessary for such reconciliation. To provide investors with additional information regarding the company's financial results, SOPHiA GENETICS has disclosed here and elsewhere in this earnings release the following non-IFRS measures: * Adjusted gross profit, which the company calculates as revenue minus cost of revenue adjusted to exclude amortization of capitalized research and development expenses; * Adjusted gross profit margin, which the company calculates as adjusted gross profit as a percentage of revenue; * Adjusted EBITDA, which the company calculates as loss for the period before depreciation, amortization, interest income, interest expense, fair value adjustments on warrant obligations, foreign exchange (losses) gains, net, income tax (expense) benefit, share-based compensation expense, social charges on share-based compensation, non-cash pension expenses, certain transaction costs, litigation expenses and restructuring costs. These non-IFRS measures are key measures used by SOPHiA GENETICS management and board of directors to evaluate its operating performance and generate future operating plans. The exclusion of certain expenses facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and certain variable charges. Accordingly, the company believes that these non-IFRS measures provide useful information to investors and others in understanding and evaluating its operating results in the same manner as its management and board of directors. These non-IFRS measures have limitations as financial measures, and you should not consider them in isolation or as a substitute for analysis of SOPHiA GENETICS' results as reported under IFRS. Some of these limitations are: * These non-IFRS measures exclude the impact of depreciation. Although depreciation is a non-cash charge, the assets being depreciated may need to be replaced in the future and these non-IFRS measures do not reflect capital expenditure requirements for such replacements or for new capital expenditures; * These non-IFRS measures exclude the impact of interest expense. Interest expense will continue to be for the foreseeable future a recurring expense based on the company's financial liabilities; * These non-IFRS measures exclude the impact of interest income. Interest income will continue to be for the foreseeable future recurring income based on the company's financial assets; * These non-IFRS measures exclude the impact of income taxes. Income taxes will continue to be for the foreseeable future a recurring expense incurred in the various jurisdictions in which the company operates; * These non-IFRS measures exclude the impact of foreign exchange gains (losses),net. Foreign exchange gains and losses will continue to be for the foreseeable future a recurring expense incurred as the company participates in transactions outside of the company's functional currency; * These non-IFRS measures exclude the impact of fair value adjustments of warrant obligations. Fair value adjustments on warrant obligations will continue to be for the foreseeable future a recurring expense incurred as the company has outstanding warrant obligations; * These non-IFRS measures exclude the impact of amortization of capitalized research and development expenses and intangible assets. Amortization of these assets will continue to be for the foreseeable future a recurring expense incurred as the Company continues to invest in developing revenue-generating products through research and development. Although amortization is a non-cash charge, the assets being amortized may need to be replaced in the future and these non-IFRS measures do not reflect capital expenditure requirements for such replacements or for new capital expenditures; * These non-IFRS measures exclude the impact of share-based compensation expenses. Share-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in the company's business and an important part of its compensation strategy; * These non-IFRS measures exclude the impact of social charges related to share-based compensation. These social charges have been, and will continue to be for the foreseeable future, a recurring expense in the company's business; * These non-IFRS measures exclude the impact of the non-cash portion of pensions paid in excess of actual contributions to match actuarial expenses. Pension expenses have been, and will continue to be for the foreseeable future, a recurring expense in the business; * These non-IFRS measures exclude the impact of certain capital markets transaction costs. These costs may occur from time to time in the future as needed to complete the transactions; * These non-IFRS measures exclude the impact of litigation expenses related to the company's defense of lawsuits filed by Guardant Health. These expenses are expected to continue for the duration of the litigation and may increase in future periods; * These non-IFRS measures exclude the costs associated with restructuring, which consists of compensation paid to employees during their garden leave period, severance, and any other amounts legally owed to the employees resulting from their termination as part of a planned workforce reduction, which we undertook to optimize our operations. Additionally, it includes any legal fees incurred as part of the restructuring process. While such actions are not planned going forward as part of our regular operations, we expect such expenses could still be incurred from time to time based on corporate needs;and * Other companies, including companies in the company's industry, may calculate these non-IFRS measures differently, which reduces their usefulness as comparative measures. Because of these limitations, you should consider these non-IFRS measures alongside other financial performance measures, including various cash flow metrics, net income and other IFRS results. The tables below provide the reconciliation of the most comparable IFRS measures to the non-IFRS measures for the periods presented. Presentation of Constant Currency Revenue SOPHiA GENETICS operates internationally, and its revenues are generated primarily in the U.S. dollar, the euro and Swiss franc and, to a lesser extent, British pound, Australian dollar, Brazilian real, Turkish lira and Canadian dollar depending on the company's customers' geographic locations. Changes in revenue include the impact of changes in foreign currency exchange rates. We present the non-IFRS financial measure "constant currency revenue" (or similar terms such as constant currency revenue growth) to show changes in revenue without giving effect to period-to-period currency fluctuations. Under IFRS, revenues received in local (non-U.S. dollar) currencies are translated into U.S. dollars at the average monthly exchange rate for the month in which the transaction occurred. When the company uses the term "constant currency", it means that it has translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the comparable reporting period of the prior year. The company then calculates the difference between the IFRS revenue and the constant currency revenue to yield the "constant currency impact" for the current period. The company's management and board of directors use constant currency revenue growth to evaluate growth and generate future operating plans. The exclusion of the impact of exchange rate fluctuations provides comparability across reporting periods and reflects the effects of customer acquisition efforts and land-and-expand strategy. Accordingly, it believes that this non-IFRS measure provides useful information to investors and others in understanding and evaluating revenue growth in the same manner as the management and board of directors. However, this non-IFRS measure has limitations, particularly as the exchange rate effects that are eliminated could constitute a significant element of its revenue and could significantly impact performance and prospects. Because of these limitations, you should consider this non-IFRS measure alongside other financial performance measures, including revenue and revenue growth presented in accordance with IFRS and other IFRS results. The table below provides the reconciliation of the most comparable IFRS growth measures to the non-IFRS growth measures for the current period. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM(TM), an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. Forward-Looking Statements This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to the company's management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company's filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company's expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. | SOPHiA GENETICS SA Interim Condensed Consolidated Statements of Loss (Amounts in USD thousands, except per share data) (Unaudited) | | / | / | Three months ended September 30, | / | Nine months ended September 30, | | / | / | 2026 | / | 2025 | / | 2026 | / | 2025 | | Revenue | / | $ 24,267 | / | $ 19,462 | / | $ 69,265 | / | $ 55,564 | | Cost of revenue | / | (8,333) | / | (6,555) | / | (23,521) | / | (18,179) | | Gross profit | / | 15,934 | / | 12,907 | / | 45,744 | / | 37,385 | | Research and development costs | / | (8,295) | / | (8,067) | / | (26,486) | / | (25,678) | | Selling and marketing costs | / | (10,578) | / | (8,670) | / | (30,577) | / | (26,238) | | General and administrative costs | / | (14,885) | / | (13,889) | / | (43,846) | / | (37,790) | | Other operating income (expense), net | / | - | / | (143) | / | 5 | / | (69) | | Operating loss | / | (17,824) | / | (17,862) | / | (55,160) | / | (52,390) | | Interest income | / | 451 | / | 622 | / | 971 | / | 1,491 | | Interest expense | / | (1,618) | / | (1,663) | / | (4,905) | / | (2,881) | | Fair value adjustments on warrant obligations | / | (1,142) | / | (607) | / | (1,551) | / | (587) | | Foreign exchange gains (losses), net | / | 175 | / | 131 | / | (660) | / | (3,546) | | Loss before income taxes | / | (19,958) | / | (19,379) | / | (61,305) | / | (57,913) | | Income tax benefit (expense) | / | (314) | / | (642) | / | (645) | / | (1,907) | | Loss for the period | / | (20,272) | / | (20,021) | / | (61,950) | / | (59,820) | | Attributable to the owners of the parent | / | (20,272) | / | (20,021) | / | (61,950) | / | (59,820) | | Basic and diluted loss per share | / | $ (0.24) | / | $ (0.30) | / | $ (0.81) | / | $ (0.89) | | SOPHiA GENETICS SA Interim Condensed Consolidated Statements of Comprehensive Loss (Amounts in USD thousands) (Unaudited) | | / | / | Three months ended September 30, | / | Nine months ended September 30, | | / | / | 2026 | / | 2025 | / | 2026 | / | 2025 | | Loss for the period | / | $(20,272) | / | $(20,021) | / | $(61,950) | / | $(59,820) | | Other comprehensive (loss) income: | / | / | / | / | / | / | / | / | | Items that may be reclassified to statement of loss | / | / | / | / | / | / | / | / | | Currency translation adjustments | / | (1,966) | / | (366) | / | (2,577) | / | 11,230 | | Total items that may be reclassified to statement of loss | / | (1,966) | / | (366) | / | (2,577) | / | 11,230 | | Items that will not be reclassified to statement of loss (net of tax) | / | / | / | / | / | / | / | / | | Remeasurement of defined benefit plans | / | 2,049 | / | 152 | / | 2,489 | / | 251 | | Total items that will not be reclassified to statement of loss | / | 2,049 | / | 152 | / | 2,489 | / | 251 | | Other comprehensive (loss) income for the period | / | $ 83 | / | $ (214) | / | $ (88) | / | $ 11,481 | | Total comprehensive loss for the period | / | $(20,189) | / | $(20,235) | / | $(62,038) | / | $(48,339) | | Attributable to owners of the parent | / | $(20,189) | / | $(20,235) | / | $(62,038) | / | $(48,339) | | SOPHiA GENETICS SA Interim Condensed Consolidated Balance Sheets (Amounts in USD thousands) (Unaudited) | | / | / | September 30, 2026 | / | December 31, 2025 | | Assets | / | / | / | / | | Current assets | / | / | / | / | | Cash and cash equivalents | / | $ 93,652 | / | $ 70,289 | | Accounts receivable | / | 16,731 | / | 15,001 | | Inventory | / | 7,160 | / | 6,351 | | Prepaids and other current assets | / | 8,087 | / | 7,438 | | Total current assets | / | 125,630 | / | 99,079 | | Non-current assets | / | / | / | / | | Property and equipment | / | 4,277 | / | 5,665 | | Intangible assets | / | 35,847 | / | 35,891 | | Right-of-use assets | / | 10,238 | / | 12,382 | | Deferred tax assets | / | 1,642 | / | 1,831 | | Other non-current assets | / | 7,097 | / | 8,183 | | Total non-current assets | / | 59,101 | / | 63,952 | | Total assets | / | $ 184,731 | / | $ 163,031 | | Liabilities and equity | / | / | / | / | | Current liabilities | / | / | / | / | | Accounts payable | / | $ 10,282 | / | $ 8,960 | | Accrued expenses | / | 22,616 | / | 20,736 | | Deferred contract revenue | / | 16,054 | / | 16,720 | | Lease liabilities, current portion | / | 2,686 | / | 2,700 | | Warrant obligations | / | 3,284 | / | 1,412 | | Total current liabilities | / | 54,922 | / | 50,528 | | Non-current liabilities | / | / | / | / | | Borrowings | / | 48,147 | / | 47,733 | | Lease liabilities, net of current portion | / | 10,207 | / | 12,587 | | Defined benefit pension liabilities | / | 1,747 | / | 4,162 | | Other non-current liabilities | / | 1,281 | / | 876 | | Total non-current liabilities | / | 61,382 | / | 65,358 | | Total liabilities | / | 116,304 | / | 115,886 | | Equity | / | / | / | / | | Share capital | / | 4,814 | / | 4,814 | | Share premium | / | 543,567 | / | 473,675 | | Treasury shares | / | (151) | / | (1,218) | | Other reserves | / | 101,423 | / | 89,150 | | Accumulated deficit | / | (581,226) | / | (519,276) | | Total equity | / | 68,427 | / | 47,145 | | Total liabilities and equity | / | $ 184,731 | / | $ 163,031 | | SOPHiA GENETICS SA Interim Condensed Consolidated Statements of Cash Flows (Amounts in USD thousands) (Unaudited) | | / | / | Nine months ended September 30, | | / | / | 2026 | / | 2025 | | Operating activities | / | / | / | / | | Loss before tax | / | $ (61,305) | / | $ (57,913) | | Adjustments for non-monetary items | / | / | / | / | | Depreciation | / | 3,209 | / | 2,949 | | Amortization | / | 5,276 | / | 4,142 | | Finance expense, net | / | 5,210 | / | 5,009 | | Fair value adjustments on warrant obligations | / | 1,551 | / | 587 | | Expected credit loss allowance increase (reversal) | / | 114 | / | (7) | | Share-based compensation | / | 12,361 | / | 12,337 | | Movements in provisions and pensions | / | 573 | / | 492 | | Research tax credit | / | (611) | / | (752) | | Gain on disposal of property and equipment | / | (7) | / | - | | Working capital changes | / | / | / | / | | Decrease (increase) in accounts receivable | / | (2,353) | / | 31 | | Decrease (increase) in prepaids and other assets | / | 604 | / | 2,060 | | Decrease (increase) in inventory | / | (1,505) | / | (165) | | Increase (decrease) in accounts payables, accrued expenses, deferred contract revenue, and other liabilities | / | 4,899 | / | 3,678 | | Cash used in operating activities | / | (31,984) | / | (27,552) | | Income tax paid | / | (306) | / | (205) | | Net cash flows used in operating activities | / | (32,290) | / | (27,757) | | Investing activities | / | / | / | / | | Purchase of property and equipment | / | (752) | / | (236) | | Acquisition of intangible assets | / | - | / | (223) | | Capitalized development costs | / | (7,132) | / | (5,697) | | Purchase of equity investments held at fair value | / | - | / | (493) | | Interest received | / | 950 | / | 1,482 | | Net cash flow used in investing activities | / | (6,934) | / | (5,167) | | Financing activities | / | / | / | / | | Proceeds from exercise of share options | / | 2,201 | / | 199 | | Interest paid | / | (4,489) | / | (2,805) | | Proceeds from borrowings, net of transaction costs | / | - | / | 34,563 | | Proceeds from sale of common stock in at-the-market offering, net of transaction costs | / | 15,667 | / | - | | Proceeds from sale of common stock in follow-on offering, net of transaction costs | / | 53,451 | / | - | | Payments of principal portion of lease liabilities | / | (1,825) | / | (1,395) | | Net cash flow provided by/(used in) financing activities | / | 65,005 | / | 30,562 | | Increase (decrease) in cash and cash equivalents | / | 25,781 | / | (2,362) | | Effect of exchange differences on cash balances | / | (2,418) | / | 3,746 | | Cash and cash equivalents at beginning of the period | / | 70,289 | / | 80,226 | | Cash and cash equivalents at end of the period | / | $ 93,652 | / | $ 81,610 | | SOPHiA GENETICS SA Reconciliation of IFRS Net Loss to Adjusted EBITDA (Amounts in USD thousands) (Unaudited) | | / | / | Three months ended September 30, | / | Nine months ended September 30, | | / | / | 2026 | / | 2025 | / | 2026 | / | 2025 | | IFRS loss for the period | / | $ (20,272) | / | $ (20,021) | / | $ (61,950) | / | $ (59,820) | | Exclude the impact of: | / | / | / | / | / | / | / | / | | Depreciation | / | $ 1,050 | / | $ 1,022 | / | $ 3,209 | / | $ 2,949 | | Amortization[(3)(4)] | / | 1,777 | / | 1,402 | / | 5,276 | / | 4,142 | | Interest income | / | (451) | / | (622) | / | (971) | / | (1,491) | | Interest expense | / | 1,618 | / | 1,663 | / | 4,905 | / | 2,881 | | Fair value adjustments on warrant obligations | / | 1,142 | / | 607 | / | 1,551 | / | 587 | | Foreign exchange gains (losses), net | / | (175) | / | (131) | / | 660 | / | 3,546 | | Income tax expense | / | 314 | / | 642 | / | 645 | / | 1,907 | | Share-based compensation expense[(1)] | / | 4,556 | / | 4,146 | / | 12,361 | / | 12,337 | | Social charges related to share-based compensation[(7)] | / | 2,804 | / | 1,317 | / | 5,112 | / | 1,312 | | Non-cash pension expense[(2)] | / | 86 | / | 87 | / | 249 | / | 262 | | Transaction costs[(5)] | / | - | / | 445 | / | 291 | / | 445 | | Litigation expenses[(6)] | / | 931 | / | 605 | / | 2,750 | / | 605 | | Restructuring costs[(8)] | / | 549 | / | - | / | 1,804 | / | - | | Adjusted EBITDA | / | $ (6,071) | / | $ (8,838) | / | $ (24,108) | / | $ (30,338) | | SOPHiA GENETICS SA Reconciliation of IFRS Revenue Growth to Constant Currency Revenue Growth (Amounts in USD thousands, except for %) (Unaudited) | | / | / | Three months ended September 30, | / | Nine months ended September 30, | | / | / | 2026 | / | 2025 | / | Growth | / | 2026 | / | 2025 | / | Growth | | IFRS revenue | / | $ 24,267 | / | $ 19,462 | / | 25 % | / | $ 69,265 | / | $ 55,564 | / | 25 % | | Current period constant currency impact | / | 167 | / | - | / | / | / | (1,769) | / | - | / | / | | Constant currency revenue | / | $ 24,434 | / | $ 19,462 | / | 26 % | / | $ 67,496 | / | $ 55,564 | / | 21 % | | SOPHiA GENETICS SA Reconciliation of IFRS to Adjusted Gross Profit and Gross Profit Margin (Amounts in USD thousands, except percentages) (Unaudited) | | / | / | Three months ended September 30, | / | Nine months ended September 30, | | / | / | 2026 | / | 2025 | / | 2026 | / | 2025 | | Revenue | / | $ 24,267 | / | $ 19,462 | / | $ 69,265 | / | $ 55,564 | | Cost of revenue | / | (8,333) | / | (6,555) | / | (23,521) | / | (18,179) | | Gross profit | / | $ 15,934 | / | $ 12,907 | / | $ 45,744 | / | $ 37,385 | | Amortization of capitalized research and development expenses[(3)] | / | 1,712 | / | 1,329 | / | 5,071 | / | 3,927 | | Adjusted gross profit | / | $ 17,646 | / | $ 14,236 | / | $ 50,815 | / | $ 41,312 | | Gross profit margin | / | 65.7 % | / | 66.3 % | / | 66.0 % | / | 67.3 % | | Amortization of capitalized research and development expenses[(3)] | / | 7.1 % | / | 6.8 % | / | 7.3 % | / | 7.1 % | | Adjusted gross profit margin | / | 72.8 % | / | 73.1 % | / | 73.3 % | / | 74.4 % | | Notes to the Reconciliation of IFRS to Adjusted Financial Measures Tables | | (1) | Share-based compensation expense represents the cost of equity awards issued to our directors, officers, and employees. The fair value of awards is computed at the time the award is granted and is recognized over the vesting period of the award by a charge to the income statement and a corresponding increase in other reserves within equity. These expenses do not have a cash impact but remain a recurring expense for our business and represent an important part of our overall compensation strategy. | | (2) | Non-cash pension expense consists of the amount recognized in excess of actual contributions made to our defined pension plans to match actuarial expenses calculated for IFRS purposes. The difference represents a non-cash expense but remains a recurring expense for our business as we continue to make contributions to our plans for the foreseeable future. | | (3) | Amortization of capitalized research and development expenses consists of software development costs amortized using the straight-line method over an estimated life of five years. These expenses do not have a cash impact but remain a recurring expense generated over the course of our research and development initiatives. | | (4) | Amortization of intangible assets consists of costs related to intangible assets amortized over the course of their useful lives. These expenses do not have a cash impact, but we could continue to generate such expenses through future capital investments. | | (5) | Transaction costs consists of expenses incurred in connection with the Company's shelf registration statement and the ATM program. | | (6) | Litigation expenses consists of expenses, net of recoveries, related to the company's defense of lawsuits filed by Guardant Health. | | (7) | Social charges related to share-based compensation consist of payroll taxes and other social charges on share-based compensation awards. These expenses have been, and will continue to be for the foreseeable future, a recurring expense in the company's business. | | (8) | Restructuring costs consists of compensation paid to employees during their garden leave period, severance, and any other amounts legally owed to the employees resulting from their termination as part of a planned workforce reduction. Additionally, it includes legal fees incurred as part of the restructuring process. | SOURCE SOPHiA GENETICS

SOPHiA GENETICS and Myriad Genetics announce new collaboration to advance prostate genomic instability score technology. 08 Oct, 2026, 18:30 IST BOSTON, Oct. 8, 2026 /PRNewswire/ - SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostic solutions. Myriad developed PrGIS to support HRD as an actionable biomarker in prostate cancer, where HRD is emerging as an important prognostic and predictive biomarker. The proprietary MyChoice(R) CDx test which is currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for prostate cancer as a new indication. "This collaboration showcases Myriad's biopharma capabilities to support development of precision oncology treatments," said Lou Welebob, Senior Vice President, Companion Diagnostics, Myriad Genetics. "PrGIS is designed to provide biopharma partners with a platform that may support patient stratification in clinical trials and help accelerate companion diagnostic development for precision oncology therapies." As part of the collaboration, SOPHiA GENETICS is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution. The solution will incorporate Myriad's PrGIS technology and aim to expand patient access to PrGIS in global markets. SOPHiA GENETICS' technology-agnostic, cloud-based platform offers local laboratory testing across a global network of more than 1,000 connected institutions in over 75 countries. "Precision medicine has a geographic problem because breakthrough therapies developed in major markets often remain inaccessible to patients in the rest of the world," said Jess Lambe, VP & Managing Director of BioPharma Business Development, SOPHiA GENETICS. "By pairing Myriad's world-class biomarker innovation with SOPHiA GENETICS' global network, we are working toward a solution for this. Together, we're building a new model for companion diagnostic deployment that could help innovative therapies reach the right patients locally, expanding access to care where it matters the most." Upcoming ESMO data to highlight PrGIS as a novel biomarker in prostate cancer Myriad also plans to present PrGIS research, co-authored with AstraZeneca, at the upcoming European Society for Medical Oncology (ESMO) Congress 2026. The research is expected to further characterize the biomarker and support its validation. Full data will be available following the ESMO embargo period. About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is an AI-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of SOPHiA DDM(TM), an AI platform that analyzes complex genomic and multimodal data to generate real-time, real-world insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. About Myriad Genetics Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com. SOPHiA GENETICS Safe Harbor Statement This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the Company's plans to deploy PrGIS technology, the development of decentralized companion diagnostic solutions, the Company's global commercialization capabilities, and the expected benefits and reach of this collaboration. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such risks and uncertainties include those described in the Company's Annual Report on Form 20-F filed on March 3, 2026, as well as any updates to those risk factors filed from time to time in the Company's Reports on Form 6-K or other filings with the U.S. Securities and Exchange Commission. SOPHiA GENETICS is not under any obligation, and expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.